(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb (NYSE:BMY) and Bain Capital have announced the establishment of a new independent biopharmaceutical ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the top low volatility healthcare stocks to buy now. On July 24, Goldman ...

Bristol Myers and Pfizer will sell Eliquis directly to U.S. patients at a discounted rate with transparent pricing and ...

Bristol Myers Squibb's first-half non- GAAP diluted earnings per share (EPS) advanced 9.6% year over year to $3.67, which is impressive growth. Upcoming blockbuster brands and an enviable pipeline ...

Bristol Myers Squibb (BMY 0.07%) is one of the best-known healthcare companies in the world. Its roots go back to the 1800s, and it has continually evolved and gotten bigger over the years.

Bristol Myers Squibb’s revenue of $11.9 billion in Q2 was up 2% y-o-y, and its EPS of $1.93 reflected an 18% growth. This compares with our estimates of $11.5 billion and $1.86, respectively.

Bristol Myers Squibb's first-half revenue advanced 8.9% year over year to $22.8 billion, which was driven by solid growth from its top three drugs -- Revlimid, Eliquis, and Opdivo.

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...

Princeton: Bristol Myers Squibb and Bain Capital have announced the formation of a new independent biopharmaceutical company, ...

Bain Capital and Bristol Myers Squibb have formed a new biopharmaceutical company focused on developing new therapies for autoimmune diseases. The newly formed company launches with a $300 million ...